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Expression of two WFDC1/ps20 isoforms in
prostate stromal cells induces paracrine
apoptosis through regulation of PTGS2/COX-2
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1Department of Infectious Disease, King’s College London, Guys Hospital, Great Maze Pond, London SE1 9RT, UK; 2Division of
Transplantation, King’s College London, Guys Hospital, Great Maze Pond, London SE1 9RT, UK; 3Genotypic Technology Pvt Ltd,
Bangalore 560094, India; 4Centre for Infectious Disease Research, Indian Institute of Science, Raman Avenue, Bangalore 560012,
India and 5Institute of Bioinformatics and Biotechnology, Biotech Park, Electronics City Phase I, Bengaluru 560 100, India
Background:WFDC1/Prostate stromal 20 (ps20) is a small secreted protein highly expressed within the prostate stroma. WFDC1/
ps20 expression is frequently downregulated or lost in prostate cancer (PCa) and ps20 has demonstrated growth-suppressive
functions in numerous tumour model systems, although the mechanisms of this phenomenon are not understood.
Methods: Ps20 was cloned and overexpressed in DU145, PC3, LNCaP and WPMY-1 cells. Cellular growth, cell cycle and apoptosis
were characterised. WPMY-1 stromal cells expressing ps20 were characterised by transcriptome microarray and the function of
WPMY-1 conditioned media on growth of PCa cell lines was assessed.
Results: Prostrate stromal 20 expression enhanced the proliferation of LNCaP cells, whereas stromal WPMY-1 cells were inhibited
and underwent increased apoptosis. Prostrate stromal 20-expressing WPMY-1 cells secrete a potently proapoptotic conditioned
media. Prostrate stromal 20 overexpression upregulates expression of cyclooxygenase-2 (COX-2) in LNCaP and WPMY-1 cells, and
induces expression of a growth-suppressive phenotype, which inhibits proliferation of PCa cells by ps20-expressing WPMY-1
conditioned media. This growth suppression was subsequently shown to be dependent on COX-2 function.
Conclusions: This work posits that expression of ps20 in the prostate stroma can regulate growth of epithelial and other tissues
through the prostaglandin synthase pathway, and thereby restricts development and progression of neoplasms. This provides a
rational for selective pressure against ps20 expression in tumour- associated stroma.
In the healthy adult prostate, stromal tissues secrete the
extracellular matrix, which preserves the architecture of the organ,
and produce soluble signals to control the growth and differentia-
tion of the epithelial compartment (Cunha et al, 1996; Ressler and
Rowley, 2011). Deregulated stroma occurs during carcinogenesis
and reciprocal signalling between neoplastic epithelium and the
surrounding stromal tissues, leading to the emergence of a ‘reactive
stroma’, which coevolves to support the growth, invasion, immune
suppression and eventual metastasis of the tumour (Niu and Xia,
2009; Feig et al, 2013). Indeed, elimination of certain stromal
compartments is sufficient to induce complete regression of
tumours in mice, highlighting the significance of a dysfunctional
stroma in tumour growth and survival (Kraman et al, 2010).
Prostrate stromal 20 (ps20) is a 24 kDa secreted protein encoded
by the WFDC1 gene. It is part of the WAP domain containing
family of proteins consisting of small secreted immunomodulatory
factors (Bingle and Vyakarnam, 2008) that are being increasingly
recognised as important regulators of cell and tumour growth
(Devoogdt et al, 2004; Bouchard et al, 2006; Madar et al, 2009;
Clauss et al, 2010). Prostrate stromal 20 was originally isolated
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from rat mesenchymal urogenital sinus cells by functional
inhibition of PC-3 cell growth (Rowley et al, 1995). The WFDC1
gene locus was identified in man at 16q24.3, a region whose loss of
heterozygosity is specifically associated with progressive prostate
cancer (PCa) (Larsen et al, 2000; Harkonen et al, 2005). Rowley
et al, (1995) subsequently identified the loss of ps20 from the
stromal compartment as a key difference between healthy speci-
mens and the reactive stroma associated with cancerous prostate
samples (McAlhany et al, 2004; Watson et al, 2004). However,
ps20-transduced xenografts achieved greater size and vascularity
than control tumours in mice (McAlhany et al, 2003), suggesting
that the function of ps20 may be tissue-specific.
Numerous other studies have identified a loss or reduction in
WFDC1 expression in PCa (Watson et al, 2004) and other cancer
types including melanoma (Liu et al, 2008), lung, brain, bladder
and fibrosarcomas (Madar et al, 2009). Herein, we investigate the
expression of WFDC1/ps20 in PCa, and demonstrate that
ps20 expression in WPMY-1 prostate stromal cells exhibits
paracrine growth suppression of PCa cells through regulation of
cyclooxygenase-2 (COX-2) expression.
MATERIALS AND METHODS
Cell lines. Cell lines PC-3, LNCaP, DU145, PNT-2 and WPMY-1
were purchased from ATCC (Manassas, VA, USA). The 293 and
HeLa cells were a gift from Professor Mike Malim (KCL,
Department of Infectious Diseases, London, UK). Cells were
cultured in DMEM (WPMY-1, 293) or RPMI (PC-3, DU145,
LNCaP, HeLa) supplemented with 10% foetal calf serum, 2mM L-
glutamine and antibiotics.
Antibodies and inhibitors. The monoclonal 1G7 anti-ps20 was
generated as described previously (Larsen et al, 1998). Polyclonal
antibodies 5301 and 650 specific to ps20 were generated by
Eurogentec (Lie`ge, Belgium) by inoculation of rabbits with the
ps20-derived peptides AEEAGAPGGPRQPRA (aa 48–63) and
KNVAEPGRGQQKHFQ (aa 205–220). The cyclooxygenase–2
inhibitor was rofecoxib (Sigma, Poole, UK).
Purification of ps20. HeLa cells were cultured in specialised
media (SFM4CHO) and harvested at 72 h. Conditioned media
(CM) were concentrated 10-fold using Vivaflow 200 (Sartorius,
Goettingen, Germany, 5 kDa MWCO PES) and applied to NHS-
activated sepharose column conjugated to anti-ps20 IG7. Prostrate
stromal 20 was eluted with 0.1M glycine (pH 3) and neutralised
immediately with 1M Tris (pH 9).
MTS viability assay. Cells were seeded at 2000 per well in 96-well
plates and cultured in the indicated conditions for the 96 h. After this
time, 15ml of Celltitre reagent was added for 1h and colorimetric
reading was taken using a plate reader (Bio-Rad, Hemel Hempstead,
UK). Where indicated, data were plotted as a percentage of a triplicate
control where cells were cultured in complete media alone.
Cell-cycle analysis. Cells were fixed in 70% EtOH, centrifuged and
resuspended in 0.05% Triton-X in PBSþ 50 mgml 1 PIþ 100
mgml 1 RNaseA at 37 1C for 45min. Excess buffer was removed
following centrifugation and cells were acquired using the FACS
Canto II (Becton Dickinson, Oxford, UK).
Annexin V staining. Apoptosis was investigated by staining cells
for annexin V expression. Treated cells were harvested from a
48- or 24-well plate and washed in annexin V binding buffer
(BioLegend, London, UK) in 5ml FACS tubes. Annexin V-APC
(BioLegend) and PI (Sigma) was added simultaneously and
incubated at RT for 30min. Cells were washed in annexin V
binding buffer and acquired using a FACS Canto II (Becton
Dickinson).
Ectopic WFDC1 expression. The WFDC1 gene was amplified
from HeLa-derived cDNA with specific primers: 50-GGGAGG
AAATGCCTTTAACC-30 and 50-TGCTTGCCGTTGCTTTACTG-30
using a One-Step RT–PCR Kit (Qiagen, Manchester, UK). EcoR1
and Xho1 sites were added through amplification with Taq
polymerase (New England Biolabs, Ipswich, MA, USA) using the
following primers: fwd, 50-ATATATACTCGAGGCATGCCTTTC
CGGC-30 and rev, 50-ATATATGAATTCGCTTACTGAAAGT
GCTTCTG-30. The resulting products were ligated using T4 ligase
(NEB) into a restriction-digested MIGR1-EGFP MLV-derived
mammalian/retroviral plasmid (a kind gift from Professor Mike
Malim). Expression in ps20 constructs in 293 cells was by
transfection of 5 105 cells in 6-well plates with 4 mg plasmid
using polyethylenimine. Media were replaced after 16 h and
harvested at 48 h.
Generation ofWFDC1 expressing transduced cell lines. Retrovirions
were generated as described previously (Lee et al, 2001) by
transfection of 293 cells with VSVg, CpG and target EV/ps20FL/
TR-MIGR1-EGFP constructs for 48 h and collecting the CM.
Target cells (WPMY-1, LNCaP, PC-3 and DU145) were plated to
50% confluency in 6-well plates. Crude CM containing virus was
added 1 : 1 with complete media and replaced after 48 h. Cells were
then sorted for cells expressing high levels of EGFP using a
FACSAria (BD Biosciences, Oxford, UK).
Quantitative real-time–PCR. Total RNA was isolated using Qiagen
RNeasy Kit (Qiagen) and reverse transcribed using the High-Capacity
Reverse Transcription Kit (Applied Biosystems, Warrington, UK). All
target primers were predesigned KiCqStart primers (Sigma). SYBR
green reagent (Qiagen), relevant primers and cDNA were combined
in 384-well plates in a ratio of 5 : 4 : 2 and amplified on an ABI7400
cycler (Applied Biosystems).
Ps20 ELISA. Plates were coated with anti-ps20 rabbit polyclonal
antibody at 8 mgml 1 overnight and blocked with 1% BSA.
One hundred microlitres of samples were incubated for 2 h.
A standard of known concentration was prepared from ps20-GST
(Proteintech, Manchester, UK). Detection was with 1G7 con-
jugated to horseradish peroxide at 3.7 mgml 1 for 2 h. Substrate
buffer (Sigma fast OPD) was added and reading was performed at
A490 nm using a colorimetric plate reader (Bio-Rad).
Western blotting. Reduced samples were run on 12% NuPage
Bis-Tris gels (Life Technologies, Paisley, UK). Protein was
transferred to nitrocellulose membranes and blocked using 5%
milk. Primary (1/500) and secondary (anti-rabbit 1/2000) anti-
bodies were incubated simultaneously overnight at 4 1C, followed
by the addition of HRP substrate (Thermo Scientific, Life
Technologies) and acquisition using the Imagequant system
(GE Healthcare, Amersham, UK).
Microarray. Five hundred nanograms of total RNA was reverse
transcribed using oligodT primer tagged to T7 promoter sequence
and converted to double-stranded cDNA in the same reaction. The
cDNA was converted to cRNA in the in vitro transcription step
using T7 RNA polymerase enzyme and Cy3 dye was incorporated
into the newly synthesised strands. Six hundred nanograms of
labelled cRNA were hybridised on the array (Agilent 8 60K GE
Human array). Normalisation and analysis was performed using
the GeneSpring GX version 12.0 software (Agilent, Cheadle, UK).
RESULTS
WFDC1 expression is downregulated in PCa. WFDC1/ps20 was
shown to be downregulated in cancers including PCa (Watson et al,
2004; Madar et al, 2009), suggesting a putative role as a tumour-
suppressive factor. We investigated the expression of WFDC1 in PCa
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using online genomic databases (Rhodes et al, 2004). We found that
WFDC1 was significantly decreased in clinical tumour samples
relative to normal prostate tissues in all but one study (Figure 1A).
Furthermore, double WFDC1 deletions were found in 6.7% of
prostate tumours (9.6–0.9% in individual studies) (Figure 1B). We
then sought to confirm the site of WFDC1 expression using a
previously performed microarray analysis of expression profiles in
different prostate cell types (Oudes et al, 2006). WFDC1 was highly
expressed in fibromuscular stromal cells but not in secretory
epithelial, basal or endothelial cells, confirming previous immuno-
histochemical analyses (McAlhany et al, 2003) (Figure 1C). Using
qPCR we found that WFDC1 expression was extremely low in all
prostate-derived cells, while fellow WAP family protein SLPI was 2–3
logs higher in all cells tested except WPMY-1 (Figure 1D).
Expression of WFDC1/ps20. Two WFDC1 mRNA species are
expressed in HeLa cells (Supplementary Figures 1a and b), a full-
length (660 bp) transcript and a truncated (576 bp) transcript in
which exon 3 is absent. Both have been identified previously in
PCa cell lines (Watson et al, 2004). Purification of ps20 from HeLa
cell CM resulted in two discreet protein species with intact N and C
termini (Supplementary Figure 1c), strongly implying that the
second ‘truncated’ WFDC1 mRNA is translated and expressed. We
cloned both WFDC1 mRNA species and produced stably
transduced PCa and WPMY-1 cell lines expressing empty vector
(EV), ps20 full-length (ps20FL) or truncated ps20 (ps20TR). In all
transduced cell lines, ps20 expression was seen at comparable levels
to HeLa and both ps20 protein species resolved at their predicted
MW by western blot (Supplementary Figures 1d and e).
Ectopic expression of ps20 inhibits growth and induces
apoptosis in a cell-specific manner. Despite secreting high levels
of ps20, no growth inhibition was seen in PC-3 or DU145 cell lines
(Figures 2A and B). However, WPMY-1 stromal cells secreting both
ps20FL and ps20TR had reduced proliferation relative to the control EV
line (Figure 2C). In contrast, expression of ps20FL increased
proliferation of LNCaP cells (Figure 2D). The WPMY-1 and LNCaP
growth increase/decrease was confirmed by cell counting of seven
passages of the transduced WPMY-1 cells (Supplementary Figures 2a
and b). Cell-cycle analysis of transduced WPMY-1 cell lines indicated
that in cells expressing ps20FL, a significantly smaller proportion of cells
were in the G2 and S phase of the cell cycle (Figure 2E), whereas the
opposite was true for LNCaP cells expressing both ps20FL and ps20TR
(Figure 2F). WPMY-1 cells expressing both ps20FL and ps20TR had a
significantly increased percentage of apoptotic cells at 48h relative to
the EV cells that was more pronounced when cultured in serum-free
media, presumably because of the absence of growth and survival
factors contained in FCS (Figure 2G). Prostrate stromal 20 had no effect
on the levels of LNCaP cells undergoing apoptosis (Figure 2H).
CM from WPMY-1 cells expressing ps20 has broad growth
inhibitory effects. As ps20 expression is reduced in PCa
(Figure 1A) and the associated stroma (McAlhany et al, 2004),
we hypothesised that stromal ps20 may be a paracrine regulator of
growth and a barrier in the development of prostate neoplasms.
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Figure 1. WFDC1 expression in the healthy and cancerous prostate. (A) WFDC1 expression is reduced in prostate cancer. The oncomine
database was queried for the expression ofWFDC1 in healthy control samples (HC) vs adenocarcinoma samples (prostate cancer (PCa)) from seven
data sets (named) and the collated total data set. The bars represent 25–75% interval of normalised WFDC1 expression levels in each group. The
deviation lines represent 10–90%. (B) Plot shows the frequency of deep WFDC1 deletions from seven data sets and the mean. (C) Data show the
expression of WFDC1 in the four predominant cell types in the prostate. Data were mined from microarray performed previously by Oudes et al
(2006), wherein cell suspensions was prepared from radical prostatectomies (n¼5) and magnetic-activated cell sorting (MACS) sorted according to
the expression of integrin b4, (basal) dipeptidyl peptidase IV (luminal secretory), integrin a1 (stromal fibromuscular) and platelet endothelial cell
adhesion molecule-1 (PECAM-1) (endothelial) as described therein. (D) Quantitative PCR (qPCR) was used to assessWFDC1 and SLPI expression in
commonly studied PCa-derived cell lines and HeLa. *Po0.05 and ***Po0.0001 by unpaired T-test (A, two-tailed; C, one-tailed). NS,
nonsignificant.
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Conditioned media from WPMY-1 cells expressing EV, ps20FL or
ps20TR potently inhibited growth of PCa cell lines (Figures 3A–C)
but, interestingly, not HeLa cells (not shown). Furthermore, ps20
WMPY-1 media conditioned for 72 h also inhibited growth when
added back onto WPMY-1 cells (Figure 3D). We failed to observe
any specific growth suppression of PCa cell lines treated with CM
from 293 cells expressing ps20 species, despite having a ps20
concentration 2 logs higher than transduced WPMY-1 lines
(Supplementary Figures 3a–d), suggesting that ps20 is not directly
inducing the observed growth suppression. Prostrate stromal 20
expressing WPMY-1 CM significantly increased annexin V
staining (Figures 3E–H), suggesting that a paracrine-induced
increase in PCa cell apoptosis is occuring. Little to no effect on
the cell cycle was observed with the same treatment (not shown).
Ps20 does not mediate growth suppression directly. Given that
CM from 293 cells expressing ps20 was unable to specifically
suppress the proliferation of PCa cell lines (Supplementary
Figure 3), we used beads coated with anti-ps20 antibody to deplete
ps20 from the WPMY-1 CM. Conditioned media from ps20FL- and
ps20TR-expressing WPMY-1 cells was successfully ps20 depleted to
the background level (Figure 4A); however, this did not have any
demonstrable effect on the ability of ps20-transduced WPMY-1
CM to inhibit proliferation (Figure 4B), suggesting that ps20 is not
mediating this effect directly. To exclude the possibility that the
WPMY-1 cells were not mediating paracrine growth suppression
by depleting the CM of vital nutrients, we treated PC-3 and DU145
cells with transduced WPMY-1 CM, which had been boiled for
20min. Boiling completely abrogated the suppressive phenotype,
suggesting that it was mediated by a factor that can be denatured
by heat, such as a protein or lipid (Figures 4C and D).
Ps20 expression regulates expression of numerous secreted
factors including PTGS-2/COX-2. We sought to identify the
differences in gene expression in WPMY-1 cells expressing ps20
species relative to EV controls. Transcriptome analysis of two
passages each of WPMY-1EV, WPMY-1-ps20FL and WPMY-1-
ps20TR cells showed significant overlap in both upregulated and
downregulated transcripts between ps20FL and ps20TR cells
(Supplementary Figures 4a–c) and subsequent pathway analysis
revealed that ps20 altered the expression of a number of cytokine/
chemokine pathways, metabolic pathways and cell adhesion
pathways (Supplementary Figure 4d). We mined the data
specifically for differentially expressed soluble factors (Table 1).
Factors with published antiproliferative effects that were upregu-
lated were SerpinF1 (pigment epithelium-derived factor) (Becerra
and Notario, 2013) and IL-32 (Joosten et al, 2013). Interleukin-8,
on the other hand, can stimulate the growth of PCa epithelium
(Waugh and Wilson, 2008). Last, we observed a marked increase in
the expression of PTGS2, which encodes a prostaglandin synthase,
COX-2, an enzyme responsible for metabolising arachidonic acid
into prostaglandin H2 (PGH2), which has diverse roles in the
control of cellular growth, including inhibiting proliferation and
the induction of apoptosis (Chaffer et al, 2006).
Expression changes of targets of interests were verified on
transduced WPMY-1 cells by qPCR. In all cases upregulation was
observed to a lesser extent in the ps20TR-expressing cells than on
those expressing ps20FL (Figure 5A), mirroring the intermediate
growth-suppressive phenotype observed in ps20TR-expressing
WPMY-1 cells relative to ps20FL. Notably, we also observed
upregulation of PTGS-2 in LNCaP cells, suggesting ps20 is able to
regulate PTGS2 expression in different cell types (Figure 5B).
WPMY-1 cells cultured in the presence of COX-2 inhibitor do
not produce growth-suppressive CM. Cyclooxygenase-2 is an
inducible enzyme, which results in the production of downstream
prostanoids including PGD2 and 15d-PGJ2. 15d-PGJ2 is present in the
prostate and seminal fluid (Tokugawa et al, 1998; Jowsey et al, 2003)
and prostate stromal-derived 15d-PGJ2 has been shown to inhibit the
growth and induce apoptosis of PCa cells (Kim et al, 2005; Nakamura
et al, 2013). We used a highly specific COX-2 inhibitor, rofecoxib
(Ehrich et al, 1999), to produce WPMY-1 CM in which the COX-2
pathway was inhibited. Figures 6A and B shows PC-3 and DU145
cells cultured in ps20-transduced WPMY-1 CM produced in the
presence of rofecoxib, or DMSO. We showed that ps20-transduced
WPMY-1 CM is no longer highly suppressive when cultured in the
presence of the COX-2 inhibitor. When added to DU145 cells,
suppression is relieved to the level observed with WPMY-1-EV
control CM, while on PC-3 cells the abrogation of suppression was
less complete, but still pronounced. This strongly suggests that
activation of the prostaglandin pathway by COX-2 is responsible for
ps20-driven growth suppression exhibited by ps20-expressing
WPMY-1 CM. To control for nonspecific effects of the COX-2
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Figure 2. Expression of prostrate stromal 20 (ps20) induces opposing
effects on stromal- and tumour-derived prostate cancer (PCa) cells.
(A–D) PC-3 (A), DU145 (B) or WPMY-1 (C) and LNCaP (D) cells
transduced to express ps20FL or ps20TR were assessed for proliferation
over time using MTS viability assay. (E and F) Transduced WPMY-1
(E) or LNCaP (F) cells were treated with RNAse and cell cycle staging
was elucidated by propidium iodide (PI) staining followed by Watson
analysis on FlowJo. (G and H) Transduced WPMY-1 (G) or LNCaP
(H) cells were stained with PI and annexin V and cells were analysed
using FACS to enumerate the percentage of cells undergoing
apoptosis. Means and s.e.m.s of three experiments. *Po0.05,
**Po0.01 and ***Po0.001 by Student’s T-test.
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inhibitor on the proliferation of cells. We cultured PC-3, WPMY-1
and DU145 cells in complete media containing rofecoxib, or the same
volume of DMSO (Figure 6C). Both DMSO and rofecoxib
demonstrated a slight increase in cell proliferation, especially when
added to WPMY-1 cells, presumably due to inhibition of background
COX-2 activity. There was no growth suppression observed in any cell
line tested, indicating that the effect of COX-2 suppression in Figures
6A and B is specific.
DISCUSSION
We sought to characterise, express and functionally elucidate the
role of stromally derived ps20 in PCa through a series of in vitro
assays. We found WFDC1 to be downregulated in PCa and the
WFDC1 locus to be frequently deleted in tumours, and nor was a
significant expression of ps20 observed in any PCa cell line tested.
This is in line with the study by Madar et al (2009) who found that
WFDC1 is absent or downregulated in tumours and in highly
proliferative and cancer-associated cells. Despite their highly
proliferative nature, we observed the expression and secretion of
two isoforms of ps20 in HeLa cells, which corresponded to those
previously identified by our lab in CD4 T cells (Alvarez et al, 2008)
and in PCa lines by others (Watson et al, 2004). Furthermore, by
probing with C- and N-terminal ps20 antibodies, we show for the
first time the secretion of a lower molecular weight ps20 species
corresponding to the smaller ‘truncated’ ps20 mRNA species, with
an exon 3, 28-amino-acid deletion.
We failed to observe ps20-dependent growth inhibition of either
PC-3, or indeed in DU145 cells, in contradiction to previous work
using soluble rat ps20 (Rowley et al, 1995), suggesting that human and
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Figure 3. Conditioned media from WPMY-1 cells expressing prostrate stromal 20 (ps20) inhibits growth and induces apoptosis in of prostate
cancer (PCa) cells. (A–D) Conditioned media taken from transduced WPMY-1 following 72h in culture was titrated onto PC-3 (A), DU145 (B),
LNCaP (C) and WPMY-1 (D) cells and cultured for 96 h. Viability was measured by MTS viability assay and plotted as a percentage of cells grown in
complete media only. (E–H) DU145 (E and F) or PC3 (G and H) cells were cultured in WPMY-1 CM (three different batches) for 48 h and then
stained with propidium iodide (PI) and annexin V to enumerate the percentage of cells undergoing apoptosis. Representative plots (E–G) and
means and s.e.m. of three experiments (F and G) are shown. *Po0.05 by Student’s T-test.
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rat ps20 may have different functions, or that soluble ps20 requires
specific biochemical processing to induce direct growth inhibition.
Prostrate stromal 20 expression enhanced the proliferation of LNCaP
cells and, in contrast, inhibited growth of WPMY-1 stromal cells by
inducing apoptosis, suggesting the producer and/or the target cell is
significant with regard to the effect of ps20 expression.
We then sought to model the expression of ps20 in healthy
prostate stroma through the expression and collection of CM from
WPMY-1 cells expressing ps20FL and ps20TR species, or an EV
control. Potent growth inhibition of numerous PCa cell lines was
induced by CM from WPMY-1 cells expressing ps20, which was
caused by induction of apoptosis. Subsequent depletion of ps20
from the highly suppressive WPMY-1 CM strongly suggested that
this growth inhibitory and proapoptotic phenotype was mediated
indirectly, likely through ps20-dependent regulation of one or
more paracrine effector molecules in WPMY-1 cells. Microarray
analysis of transduced WPMY-1 cell lines identified numerous
secreted targets upregulated in WPMY-1 cells. However, most
notably, PTGS-2, which encodes the enzyme COX-2, was
upregulated by WFDC1 expression in LNCaP and WPMY-1 cells.
Addition of the highly specific inhibitor of COX-2 (rofecoxib) to
WPMY-1 cell cultures before transfer of media onto PCa cells
confirmed that the growth-suppressive effect of ps20-expressing
WPMY-1 cells was dependent on COX-2.
Cyclooxygenase-2 lies at the start of the prostanoid pathway,
converting arachidonic acid to PGH2. Further enzymes then
catalyse the formation of downstream prostanoids, many of which
are known to have potent effects of cellular growth such as PGD2,
which is found in the seminal fluid (Tokugawa et al, 1998). PGD2
is spontaneously dehydrated into 15-deoxy-D12–14-PGJ2, which
has been shown to be a potent inhibitor of PCa cell proliferation
(Chaffer et al, 2006; Nagata et al, 2008). Although we did not
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Figure 4. Suppression of PCa cell growth by WPMY-1 CM is not mediated directly by ps20. (A) Conditioned media from transduced WPMY-1
cells was incubated overnight with beads conjugated to anti-ps20 ab1G7 or a control antibody overnight and assayed by ps20 enzyme-linked
immunosorbent assay (ELISA). (B) Prostrate stromal 20 depleted or control transduced WPMY-1 CM was titrated onto WPMY-1 cells and
cultured for 96 h followed by MTS viability assay. (C and D) WPMY-1 CM was then subjected to 20min boiling at 95 1C before addition to
either DU145 (C) or PC-3 (D) cells for 96 h followed by readout by the addition of MTS viability assay.
Table 1. Growth inhibitory and secreted factors differentially
expressed in ps20-transduced WPMY-1 cells
WPMY-ps20FL WPMY-ps20TR
Gene Log2 fc P-value Log2 fc P-value
PTGS2a þ5.29 0.01 þ 3.86 0.01
CXCL11 þ4.51 0.03 — —
CXCL6a þ3.78 0.01 þ 4.22 0.01
CSF3 — — þ 3.76 0.04
CCL5 þ3.66 0.03 — —
IL4I1 — — þ 3.56 0.00
C3 þ3.51 0.03 þ 3.07 0.00
CXCL2 þ3.25 0.04 — —
IL8a þ3.00 0.01 þ 2.99 0.01
SERPINC1 — — þ 2.84 0.05
SERPINF1a þ2.72 0.00 þ 2.72 0.00
SERPING1 þ2.72 0.05 — —
IL33 þ2.57 0.00 — —
IL11 — — þ 2.32 0.01
IL32 þ2.28 0.01 — —
LIF — — þ 2.06 0.04
SERPINB9 — — þ 2.06 0.04
CXCL14 2.95 0.02 —
FGF1 3.60 0.03 —
Abbreviations: fc¼ fold change; ps20¼prostrate stromal 20; ps20FL¼ps20 full length; or
ps20TR¼ truncated ps20.
aRegulated in both ps20FL- and ps20TR-expressing cells.
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observe any 15-deoxy-D12–14-PGJ2 in CM from ps20-expressing
cells (not has been shown), there are numerous prostanoids and
other mediators downstream of COX-2, which may be able to
induce proapoptotic effects.
We hypothesise that where ps20 is expressed in the healthy
prostate stroma, it acts to induce COX-2 expression and regulate
the growth-suppressive and proapoptotic environment, placing a
restraint on epithelial growth preventing the emergence of
neoplastic tissue. Furthermore, we propose that the loss of ps20
expression in tumours demonstrated previously (McAlhany et al,
2004; Watson et al, 2004; Madar et al, 2009) is driven by selective
pressure on the tumours to escape this mechanism of growth
suppression. Further experiments are required to confirm the
exact mechanism of COX-2-dependent suppression induced by
ps20 expression. It will be important to elucidate (i) how ps20
expression is regulated, (ii) the mechanisms by which ps20
expression is suppressed in cancer and (iii) how ps20 regulates
the expression of COX-2.
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